bioRxiv Science⌕ Search

Biology subjects

Akter, D.

Publications and source records attributed to Akter, D..

2 recordsLinked to original sources

Human cytomegalovirus triggered necroptosis is suppressed by sequestration of MLKL in the nucleus of infected monocytes

The systemic spread of human cytomegalovirus (HCMV) is associated with severe morbidity and mortality in immunocompromised and immunonaive patients. Hematogenous dissemination of HCMV to different organ sites is facilitated by peripheral blood monocytes. Circulating monocytes have a short lifespan due, in part, to their intrinsic biological programming to initiate caspase 8-mediated apoptosis upon entry into the circulation from the bone marrow. We previously reported that HCMV extends the lifespan of infected monocytes by blocking procaspase 8 cleavage, yet the precise viral mechanism responsible for suppressing caspase 8 activity remains unknown. Here, we demonstrate that HCMV entry into monocytes rapidly increases the abundance of the antiapoptotic cellular FLICE-like inhibitory protein long (cFLIPL), which prevents procaspase 8 cleavage into active caspase 8. However, others have demonstrated that inhibition of caspase 8 opens a "trapdoor" cell death response termed necroptosis. Accordingly, we found the increased levels of cFLIPL, along with a co-stimulatory signal from toll like receptor 3 (TLR3), activates the receptor-interacting protein kinase 3 (RIPK3) responsible for initiating necroptosis. Despite triggering of the necroptotic cascade within infected monocytes, the final execution of this death pathway is thwarted by nuclear sequestering of mixed lineage kinase domain like pseudokinase (MLKL), the executioner of necroptosis. Together, our data reveal a multitude of countermeasures employed by HCMV to obstruct cellular antiviral death responses within infected monocytes. ImportanceHCMV is highly prevalent in the adult population with a seroprevalence of 50-80% in the United States. Although immunocompetent individuals are generally asymptomatic, HCMV infection can cause multiorgan disease in immunocompromised and immunonaive patients. Peripheral blood monocytes are responsible for the systemic dissemination of HCMV. However, the inherently short lifespan of monocytes combined with the induction of antiviral cellular death responses requires HCMV to circumvents cell death pathways to allow for viral spread. In this work, we show that HCMV induces cFLIPL levels to inhibit caspase 8-mediated apoptosis. However, the inhibition of apoptosis, combined with TLR3 activation, triggers a secondary cell death pathway termed necroptosis. As a countermeasure to block necroptosis, HCMV sequesters MLKL within the nucleus of infected monocytes. Defining the precise mechanisms through which HCMV stimulates survival will provide insight into novel therapeutics able to target infected monocytes.

microbiology↗

Targeting the host transcription factor HSF1 prevents human cytomegalovirus replication in vitro and in vivo

FDA-approved antivirals against HCMV have several limitations, including only targeting the later stages of the viral replication cycle, adverse side effects, and the emergence of drug-resistant strains. Antivirals targeting host factors specifically activated within infected cells and necessary for viral replication could address the current drawbacks of anti-HCMV standard-of-care drugs. In this study, we found HCMV infection stimulated the activation of the stress response transcription factor heat shock transcription factor 1 (HSF1). HCMV entry into fibroblasts rapidly increased HSF1 activity and subsequent relocalization from the cytoplasm to the nucleus, which was maintained throughout viral replication and in contrast to the transient burst of activity induced by canonical heat shock. Prophylactic pharmacological inhibition or genetic depletion of HSF1 prior to HCMV infection attenuated the expression of all classes of viral genes, including immediate early (IE) genes, and virus production, suggesting HSF1 promotes the earliest stages of the viral replication cycle. Therapeutic treatment with SISU-102, an HSF1 inhibitor tool compound, after IE expression also reduced the levels of L proteins and progeny production, suggesting HSF1 regulates multiple steps along the HCMV replication cycle. Leveraging a newly developed human skin xenograft transplant murine model, we found prophylactic treatment with SISU-102 significantly attenuated viral replication in transplanted human skin xenografts as well as viral dissemination to distal sites. These data demonstrate HCMV infection rapidly activates and relocalizes HSF1 to the nucleus to promote viral replication, which can be exploited as a host-directed antiviral strategy. One Sentence SummaryInhibiting of HSF1 as a host-directed antiviral therapy attenuates HCMV replication in vitro and in vivo.

microbiology↗